Market Price

29.00 

-0.60 -2.0%

as of Sep 29 '22

52 Week Range:

15.40 39.80


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 6.72
5.94
5.99
7.48
6.96
7.94
growth rate -11.6% 0.8% 24.9% -7.0% 14.1%
Earnings BIT -17.98
-3.60
15.78
-3.91
-8.62
-0.04
13.25
71.69
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% 440.9%
Avg.PE 37.08
57.69
211.84
170.00
170.00
170.00
170.00
growth rate 55.6% 267.2% -19.8% 0.0% 0.0% 0.0%
ROA 5.70
3.62
-2.94
-0.72
2.58
1.02
-1.19
8.89
0.23
9.54
growth rate -36.5% -100.0% 0.0% 100.0% -60.5% -100.0% 100.0% -97.4% 4,047.8%
ROE 7.75
4.89
-4.01
-0.97
3.37
1.35
-1.71
13.71
0.36
14.65
growth rate -36.9% -100.0% 0.0% 100.0% -59.9% -100.0% 100.0% -97.4% 3,969.4%
ROIC 6.81
4.46
-3.43
-0.72
3.14
1.26
-1.53
11.62
0.26
12.22
growth rate -34.5% -100.0% 0.0% 100.0% -59.9% -100.0% 100.0% -97.8% 4,600.0%
Cur. Ratio 2.76
2.64
3.16
2.93
3.03
2.79
2.06
2.84
2.49
3.06
growth rate -4.4% 19.7% -7.3% 3.4% -7.9% -26.2% 37.9% -12.3% 22.9%
Quick Ratio 1.47
1.23
1.45
1.66
1.64
1.64
1.32
1.46
1.53
2.08
growth rate -16.3% 17.9% 14.5% -1.2% 0.0% -19.5% 10.6% 4.8% 36.0%
Leverage 1.36
1.35
1.38
1.32
1.30
1.35
1.54
1.54
1.56
1.51
growth rate -0.7% 2.2% -4.4% -1.5% 3.9% 14.1% 0.0% 1.3% -3.2%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 23.13
33.47
26.80
42.03
52.21
45.69
66.39
78.93
growth rate 44.7% -19.9% 56.8% 24.2% -12.5% 45.3% 18.9%
Acct.Payable 10.16
13.87
19.93
16.63
31.32
25.06
24.36
22.21
growth rate 36.5% 43.7% -16.6% 88.4% -20.0% -2.8% -8.8%
Cur.Assets 198.00
175.93
184.10
187.78
220.34
255.24
279.68
318.12
growth rate -11.1% 4.6% 2.0% 17.3% 15.8% 9.6% 13.7%
Total Assets 389.37
390.14
427.74
451.07
513.56
586.97
631.24
671.53
growth rate 0.2% 9.6% 5.5% 13.9% 14.3% 7.5% 6.4%
Cash 67.83
66.07
72.35
65.59
86.34
73.69
92.64
126.35
growth rate -2.6% 9.5% -9.3% 31.6% -14.7% 25.7% 36.4%
Inventory 82.33
70.67
79.75
63.61
69.32
110.50
96.83
92.81
growth rate -14.2% 12.9% -20.2% 9.0% 59.4% -12.4% -4.2%
Cur.Liabilities 62.60
59.96
60.62
67.19
106.83
90.01
112.20
103.81
growth rate -4.2% 1.1% 10.9% 59.0% -15.8% 24.7% -7.5%
Liabilities 107.51
94.63
98.48
117.34
149.20
159.44
182.51
226.01
growth rate -12.0% 4.1% 19.1% 27.2% 6.9% 14.5% 23.8%
LT Debt 36.11
30.17
32.36
39.49
30.93
38.58
33.58
74.62
growth rate -16.5% 7.3% 22.0% -21.7% 24.8% -13.0% 122.3%
Equity 281.86
295.51
329.26
333.74
332.44
381.37
402.31
445.52
growth rate 4.8% 11.4% 1.4% -0.4% 14.7% 5.5% 10.7%
Common Shares 8.00
8.00
8.00
42.00
45.00
48.00
48.00
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 425.0% 7.1% 6.7% 0.0% -100.0% 0.0% 0.0% 20.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 20.50
16.00
21.38
35.10
46.81
41.56
33.86
27.46
growth rate -22.0% 33.7% 64.2% 33.4% -11.2% -18.5% -18.9%
Cash From OA 21.05
10.68
38.56
39.21
38.19
41.76
57.27
97.99
growth rate -49.3% 261.0% 1.7% -2.6% 9.4% 37.1% 71.1%
FCF per Share 0.16
0.23
-0.17
0.05
0.21
0.79
growth rate 43.8% -100.0% 100.0% 320.0% 276.2%
Sale Purchase of Stock 38.20
14.31
21.50
13.76
growth rate -62.5% 50.3% -36.0%
FCF 8.00
-27.00
13.00
1.00
-5.00
17.00
4.00
-9.00
0.21
23.00
71.00
growth rate -100.0% 100.0% -92.3% -100.0% 100.0% -76.5% -100.0% 100.0% 11,011.1% 208.7%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 210.46
251.52
255.17
240.18
294.67
322.36
349.85
437.77
growth rate 19.5% 1.5% -5.9% 22.7% 9.4% 8.5% 25.1%
Op.Income -17.98
-3.60
15.78
-3.91
-8.62
-0.04
13.25
71.69
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% 440.9%
IBT -18.15
-10.36
14.63
1.25
-9.93
60.23
4.64
83.93
growth rate 0.0% 100.0% -91.5% -100.0% 100.0% -92.3% 1,710.0%
Net Income -10.70
-2.79
9.82
3.65
-5.74
48.94
1.40
62.12
growth rate 0.0% 100.0% -62.9% -100.0% 100.0% -97.1% 4,327.4%
EPS 0.96
2.26
1.48
-0.25
-0.06
0.21
0.08
-0.12
0.98
0.03
1.25
growth rate 135.4% -34.5% -100.0% 0.0% 100.0% -61.9% -100.0% 100.0% -96.9% 4,066.7%
Gross Profit 51.26
77.35
104.20
90.51
106.99
131.92
143.34
199.74
growth rate 50.9% 34.7% -13.1% 18.2% 23.3% 8.7% 39.4%
R&D 28.87
37.27
41.52
43.50
57.56
68.85
67.23
60.93
growth rate 29.1% 11.4% 4.8% 32.3% 19.6% -2.4% -9.4%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 10.31
10.56
24.77
26.05
21.61
growth rate 2.5% 134.6% 5.2% -17.0%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 78.74
68.61
78.61
78.93
73.39
growth rate -12.9% 14.6% 0.4% -7.0%
Acct.Payable 22.99
27.75
21.66
22.21
23.84
growth rate 20.7% -22.0% 2.6% 7.3%
Cur.Assets 300.16
310.97
303.67
318.12
364.42
growth rate 3.6% -2.4% 4.8% 14.6%
Total Assets 645.74
665.75
651.68
671.53
716.24
growth rate 3.1% -2.1% 3.1% 6.7%
Cash 101.60
105.43
106.61
126.35
172.63
growth rate 3.8% 1.1% 18.5% 36.6%
Inventory 97.11
97.93
100.24
92.81
95.15
growth rate 0.9% 2.4% -7.4% 2.5%
Cur.Liabilities 127.10
124.55
97.99
103.81
114.36
growth rate -2.0% -21.3% 5.9% 10.2%
Liabilities 194.78
198.52
221.50
226.01
236.71
growth rate 1.9% 11.6% 2.0% 4.7%
LT Debt 31.82
29.98
75.08
74.62
74.01
growth rate -5.8% 150.4% -0.6% -0.8%
Equity 405.56
421.99
430.18
445.52
479.53
growth rate 4.1% 1.9% 3.6% 7.6%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 7.62
5.74
7.22
6.88
6.14
growth rate -24.6% 25.7% -4.7% -10.7%
Cash From OA 22.83
32.16
2.57
40.44
50.77
growth rate 40.9% -92.0% 1,474.2% 25.5%
Sale Purchase of Stock
growth rate
FCF 15.21
26.42
-4.65
33.56
44.63
growth rate 73.7% -100.0% 100.0% 33.0%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 103.02
101.66
112.20
120.89
120.37
growth rate -1.3% 10.4% 7.7% -0.4%
Op.Income 10.31
10.56
24.77
26.05
21.61
growth rate 2.5% 134.6% 5.2% -17.0%
IBT 5.11
14.22
37.65
26.95
28.33
growth rate 178.0% 164.8% -28.4% 5.1%
Net Income 5.04
7.77
29.55
19.76
24.25
growth rate 54.1% 280.4% -33.1% 22.7%
Gross Profit 44.95
47.38
51.18
56.23
55.83
growth rate 5.4% 8.0% 9.9% -0.7%
R&D 14.77
18.12
10.76
17.29
16.22
growth rate 22.7% -40.6% 60.7% -6.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (77.59)

YOY Growth Grade:

D (36.15)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 1,112.00 1,160.00 19.86
EPS / Growth -7.5% 0.03 25.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 8.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 4.5% 4.5%
Future PE 2.00 14.47 14.47
Future EPS 0.03 0.04 0.04
Value Price
MOS %
0.01
-100.0%
0.14
-99.5%
0.14
-99.5%
MOS Price 0.01 0.07 0.07
IRT 99.00 88.72 88.72

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.